Moderna’s mFlusiva: A Revolutionary mRNA Flu Vaccine for Adults Aged 50+
In a groundbreaking development in vaccine science, the U.S. Food and Drug Administration has granted approval to Moderna’s mFlusiva (mRNA-1010). This is the first-ever mRNA-based seasonal influenza vaccine, specifically designed for adults aged 50 and older. The approval comes just in time for the 2026–2027 flu season.
This revolutionary vaccine utilizes the same advanced messenger RNA technology that played a pivotal role in ending the COVID-19 pandemic. In a comprehensive late-stage clinical trial involving over 40,000 participants, mFlusiva demonstrated to be approximately 27% more effective than traditional flu shots in preventing illness in adults aged 50 to 64. Consequently, the FDA granted full approval for this age group and accelerated approval for adults 65 and older, pending further clinical data for this older age group.
What sets mFlusiva apart from conventional flu vaccines — which depend on inactivated virus grown in eggs or cells — is its unique mechanism of action. mFlusiva operates by delivering a small snippet of genetic code that instructs the body to produce a harmless viral protein, thereby triggering a robust immune response. Importantly, the mRNA technology facilitates rapid updating and manufacturing of vaccines, a critical advantage considering the fast-paced evolution of flu strains each season.
Moderna’s CEO, Stéphane Bancel, hailed mFlusiva as “an important new option for America’s seniors.” The company anticipates the vaccine to be available at select retailers for the forthcoming respiratory virus season. The shot is also currently under regulatory review in Europe, Canada, and Australia.
Source: Healthline – FDA Approves First mRNA Flu Vaccine for Older Adults (August 12, 2026)